Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 13, 2023
Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1B Besse, E Felip, R Garcia Campelo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 20, 2025
DNA methyltransferase 3A (DNMT3A) mutations and PD-(L)1 blockade efficacy in non-small-cell lung cancerB Ricciuti, S Scalera, X Wang, et al.
ESMO Open|August 30, 2024
MET exon 14 skipping mutations in non-small-cell lung cancer: real-world data from the Italian biomarker ATLAS databaseM L Reale, F Passiglia, F Cappuzzo, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|October 21, 2019
Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective studyE Gobbini, R Chiari, P Pizzutillo, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 24, 2020
Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European expertsP M Putora, G F Fischer, M Früh, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 16, 2022
Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinomaS Scalera, B Ricciuti, M Mazzotta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 25, 2023
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 studyA Passaro, J Wang, Y Wang, et al.
NPJ Precision Oncology|April 10, 2026
The role of the molecular tumor board: learnings from the ROME trialP Marchetti, G Curigliano, C B Westphalen, et al.
ESMO Open|January 24, 2026
Global advances and future directions in lung cancer care: expert consensus and strategic prioritiesM-L Meyer, S Peters, P A Jänne, et al.
Pageof 6